Clinical trial
Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: a Double-blind Placebo-controlled Efficacy Study
NCT00663858 is registered in ClinicalTrials.gov with AEterna Zentaris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: a Double-blind Placebo-controlled Efficacy Study
- Lead sponsor
- AEterna Zentaris
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- January 31, 2010
- Enrollment
- 420 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.
benign prostatic hypertrophy